Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
GTBP 
GT Biopharma Inc (GTBP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: GTBP (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $11
1 Year Target Price $11
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -48.69% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 2.43M USD | Price to earnings Ratio - | 1Y Target Price 11 |
Price to earnings Ratio - | 1Y Target Price 11 | ||
Volume (30-day avg) 1 | Beta 1.32 | 52 Weeks Range 0.55 - 4.10 | Updated Date 10/17/2025 |
52 Weeks Range 0.55 - 4.10 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.98 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -82.45% | Return on Equity (TTM) -181.99% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -7503112 | Price to Sales(TTM) - |
Enterprise Value -7503112 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.09 | Shares Outstanding 3557502 | Shares Floating 2183915 |
Shares Outstanding 3557502 | Shares Floating 2183915 | ||
Percent Insiders 20.5 | Percent Institutions 15.16 |
Upturn AI SWOT
GT Biopharma Inc
Company Overview
History and Background
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on developing innovative immunotherapies based on its TriKEu00ae and TetraKEu2122 technology platforms. Founded to leverage the power of the immune system to fight cancer, the company is pioneering novel approaches to target and eliminate cancer cells.
Core Business Areas
- TriKEu00ae and TetraKEu2122 Technology: Development of immunotherapies using its TriKEu00ae and TetraKEu2122 platforms, which are designed to enhance the immune system's ability to target and kill cancer cells. These platforms leverage natural killer (NK) cells to combat tumors.
Leadership and Structure
The leadership team includes experienced professionals in the biopharmaceutical industry, focusing on research and development, clinical trials, and corporate strategy. The company's structure involves departments dedicated to research, clinical development, manufacturing, and business operations.
Top Products and Market Share
Key Offerings
- GTB-3550 TriKEu00ae: GTB-3550 is the lead TriKEu00ae candidate, targeting CD33+ tumors in hematologic malignancies like acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Market share data is currently unavailable due to its development stage. Competitors in AML treatment include companies developing other immunotherapies, chemotherapy regimens, and targeted therapies.
- GTB-4550 TetraKEu2122: GTB-4550 is the lead TetraKE candidate, targeting CD33+ tumors and expressing PD-L1 checkpoint. The company believes this is more powerful than TriKE. Competitors in AML treatment include companies developing other immunotherapies, chemotherapy regimens, and targeted therapies.
Market Dynamics
Industry Overview
The biopharmaceutical industry is currently experiencing growth driven by advancements in immunotherapy, targeted therapies, and personalized medicine. There is high demand for innovative cancer treatments, particularly in areas with unmet medical needs.
Positioning
GT Biopharma is positioned as an innovator in the immunotherapy space, focusing on leveraging NK cell activity through its TriKEu00ae and TetraKEu2122 platforms. Its competitive advantage lies in its novel approach to redirecting NK cells to specifically target and kill cancer cells.
Total Addressable Market (TAM)
The total addressable market for cancer immunotherapies is estimated to be in the billions of dollars, and growing. GT Biopharma is positioned to capture a portion of this market with its novel NK cell engager technology.
Upturn SWOT Analysis
Strengths
- Novel TriKEu00ae and TetraKEu2122 technology platforms
- Potential for targeted cancer therapy with reduced toxicity
- Focus on unmet medical needs in hematologic malignancies
- Experienced leadership team
Weaknesses
- Early stage of development (clinical trials ongoing)
- Reliance on funding and partnerships
- Competition from established pharmaceutical companies
- Limited commercialized products
Opportunities
- Positive clinical trial results leading to regulatory approval
- Partnerships with larger pharmaceutical companies for development and commercialization
- Expansion of TriKEu00ae and TetraKEu2122 technology to other cancer types
- Growing demand for innovative cancer immunotherapies
Threats
- Clinical trial failures or delays
- Competition from other immunotherapy approaches
- Regulatory hurdles and approval delays
- Difficulty in securing funding and partnerships
Competitors and Market Share
Key Competitors
- BMY
- MRTX
- TMO
Competitive Landscape
GT Biopharma faces intense competition from established pharmaceutical companies and other biotechs developing cancer immunotherapies. Its competitive advantage lies in its novel TriKEu00ae and TetraKEu2122 technology, but it needs to demonstrate clinical efficacy and secure partnerships to compete effectively.
Growth Trajectory and Initiatives
Historical Growth: GT Biopharma's growth has been driven by advancements in its TriKEu00ae and TetraKEu2122 technology platforms and progress in clinical trials.
Future Projections: Future growth is dependent on successful clinical trial results, regulatory approvals, and commercialization partnerships. Analyst estimates vary widely due to the inherent risks associated with biopharmaceutical development.
Recent Initiatives: Recent initiatives include advancing GTB-3550 and GTB-4550 through clinical trials, securing partnerships for development and commercialization, and expanding the TriKEu00ae and TetraKEu2122 platforms to new cancer targets.
Summary
GT Biopharma is a clinical-stage company with a novel immunotherapy platform. Its TriKEu00ae and TetraKEu2122 technologies have the potential to revolutionize cancer treatment. However, the company faces significant risks associated with clinical trials and competition. Positive clinical data and successful partnerships are crucial for future success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
- Analyst reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Investment decisions should be based on thorough research and consultation with a financial advisor. Market share data is approximate and based on available information.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About GT Biopharma Inc
Exchange NASDAQ | Headquaters San Francisco, CA, United States | ||
IPO Launch date 2017-09-22 | CEO & Executive Chairman Mr. Michael Martin Breen L.L.B. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 1 | Website https://www.gtbiopharma.com |
Full time employees 1 | Website https://www.gtbiopharma.com | ||
GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) fusion protein immune cell engager technology platforms. It develops GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550 that targets B7-H3 on the surface of advanced solid tumors; and GTB-7550, a product candidate in development for the treatment of lupus and other autoimmune disorders. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.